Ascendis Pharma A (ASND) Non-Current Debt (2021 - 2025)

Ascendis Pharma A (ASND) has 5 years of Non-Current Debt data on file, last reported at $448.5 million in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Debt rose 14.95% year-over-year to $448.5 million; the trailing twelve-month figure through Dec 2025 stood at $448.5 million (up 14.95% YoY), and the FY2025 full-year result was $448.5 million, up 13.49% from the prior year.
• Non-Current Debt improved to $448.5 million in Q4 2025, from $390.1 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $448.5 million in Q4 2025 to a low of $112.1 million in Q4 2021.
• A 5-year average of $317.2 million and a median of $390.1 million in 2024 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt jumped 252.82% in 2022 and sank 39.32% in 2023, its largest moves.
• Tracing ASND's Non-Current Debt over 5 years: stood at $112.1 million in 2021, then jumped by 252.82% to $395.4 million in 2022, then slumped by 39.32% to $239.9 million in 2023, then jumped by 62.6% to $390.1 million in 2024, then increased by 14.95% to $448.5 million in 2025.
• Business Quant data shows ASND's Non-Current Debt at $448.5 million in Q4 2025, $390.1 million in Q4 2024, and $239.9 million in Q4 2023.